In addition, pembrolizumab and other ICIs combined with platinum or bevacizumab have become one of the first‐line treatment of choice for NSCLC without oncogenic drivers, irrespective of PD‐L1 expression.17, 18. This evidence concerns the gene CD274 and non-small cell lung carcinoma.